Home |
Free Dividend Report |
SGYP Dividend History |
SGYP Stock Split History |
Preferred Stock Newsletter |
SGYP Options Chain |
SGYP Message Board |

SGYP (SGYP) has 1 split in our SGYP split history database. The split for SGYP took place on February 11, 2014. This was a 1014 for 1000 split, meaning for each 1000 shares of SGYP owned pre-split, the shareholder now owned 1014 shares. For example, a 1000 share position pre-split, became a 1014 share position following the split.
When a company such as SGYP splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the SGYP split history from start to finish, an original position size of 1000 shares would have turned into 1014 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SGYP shares, starting with a $10,000 purchase of SGYP, presented on a split-history-adjusted basis factoring in the complete SGYP split history.
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 04/29/2015 | |
End date: | 04/08/2019 | |
Start price/share: | $3.69 | |
End price/share: | $0.03 | |
Dividends collected/share: | $0.00 | |
Total return: | -99.19% | |
Average Annual Total Return: | -70.47% | |
Starting investment: | $10,000.00 | |
Ending investment: | $81.30 | |
Years: | 3.95 |
![]() |
About SGYP |
Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Co. is engaged in the discovery, research and development activities around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Co. discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform. Co.'s commercial product, plecanatide, under trademark name TRULANCE is for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. According to our SGYP split history records, SGYP has had 1 split. |
SGYP Split History Table | |
Date | Ratio |
02/11/2014 | 1014 for 1000 |
Healthcare Stock Splits |
SGYP is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
SHPH Split History Also explore: SGYP shares outstanding history
|
SGYP Split History | www.SplitHistory.com | Copyright © 2013 - 2025, All Rights Reserved
Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.Want to receive our latest research absolutely free?
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.